RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from growing. Giving vaccine therapy together with GM-CSF may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.

开始日期2006-10-01

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+2]

100 项与 WT-1 analog peptide vaccine(NCI) 相关的临床结果

登录后查看更多信息

100 项与 WT-1 analog peptide vaccine(NCI) 相关的转化医学

登录后查看更多信息

100 项与 WT-1 analog peptide vaccine(NCI) 相关的专利（医药）

登录后查看更多信息

项与 WT-1 analog peptide vaccine(NCI) 相关的文献（医药）

2020-06-01·Pediatrics International

¹³¹I‐MIBG therapy with WT‐1 peptide for refractory neuroblastoma

Article

作者: Hosoya, Yosuke ; Manabe, Atsushi ; Sugiyama, Minako ; Seigo, Kinuya ; Iguchi, Akihiro

This article describes about the ¹³¹I-MIBG therapy with WT-1 peptide for refractory neuroblastoma.After a chemotherapy course of vincristine, irinotecan, and cyclophosphamide and two chemotherapy courses of etoposide, cyclophosphamide, and topotecan, peripheral blood stem cell harvest (PBSCH) was performed.Subsequently, chemotherapy courses were administered after resecting the right adrenal tumor.

2010-10-01·Cancer Immunology, Immunotherapy2区 · 医学

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

2区 · 医学

Article

作者: Sara Bekele ; Jedd Wolchok ; Tatyana Korontsvit ; Tao Dao ; Peter Maslak ; Jianda Yuan ; Hao Li ; Lee M. Krug ; Victoria Zakhaleva ; David A. Scheinberg ; William Travis ; Andrew B. Brown ; Leslie Tyson

BACKGROUNDThe transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis. Using computer prediction analysis we designed analog peptides derived from WT1 sequences by substituting amino acids at key HLA-A0201 binding positions. We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1.METHODSTherapy consisted of six subcutaneous vaccinations administered with Montanide adjuvant on weeks 0, 4, 6, 8, 10, and 12, with 6 additional monthly injections for responding patients. Injection sites were pre-stimulated with GM-CSF (70 mcg). Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells.RESULTSNine patients with MPM and 3 with NSCLC were vaccinated, with 8 patients receiving at least 6 vaccinations; in total, 10 patients were evaluable for immune response. Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response. Stimulated T cells were capable of cytotoxicity against WT-1 positive cells. Vaccination also induced polyfunctional CD8 T cell responses.CONCLUSIONSThis multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity. A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.

100 项与 WT-1 analog peptide vaccine(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床1期	美国	National Cancer Institute	2006-10-01
急性髓性白血病	临床1期	美国	Innovive Pharmaceuticals, Inc.	2006-10-01
恶性间皮瘤	临床1期	美国	Innovive Pharmaceuticals, Inc.	2006-10-01
恶性间皮瘤	临床1期	美国	National Cancer Institute	2006-10-01
骨髓增生异常综合征	临床1期	美国	National Cancer Institute	2006-10-01
骨髓增生异常综合征	临床1期	美国	Innovive Pharmaceuticals, Inc.	2006-10-01
非小细胞肺癌	临床1期	美国	National Cancer Institute	2006-10-01
非小细胞肺癌	临床1期	美国	Innovive Pharmaceuticals, Inc.	2006-10-01
腹膜癌	临床1期	美国	National Cancer Institute	2006-10-01
腹膜癌	临床1期	美国	Innovive Pharmaceuticals, Inc.	2006-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00398138 (CTgov)	临床1期	急性髓性白血病 \| 恶性间皮瘤 \| 非小细胞肺癌 \| 骨髓增生异常综合征 \| 腹膜癌	22	immunoenzyme technique+WT-1 analog peptide vaccine+sargramostim	選鹽窪鹹製製襯醖壓齋(範積餘齋艱壓鹽繭網獵) = 鏇醖觸醖艱積遞糧鑰糧選繭蓋膚夢製獵範窪鏇 (鹽範蓋願簾鑰膚艱製糧, 膚鏇鏇鑰壓鹹積齋壓淵 ~ 艱鹹觸繭鹹壓積艱鹽繭) 更多	-	2016-03-02